Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan Jun 23, 2021
Poxel Announces Participation and Presentations at the EASL (European Association for the Study of the Liver) International Liver CongressTM 2021 Jun 21, 2021
Poxel Presents New Results of Imeglimin Phase 2 and 3 Clinical Studies in Japan at the 64th Annual Meeting of the Japan Diabetes Society (JDS) May 20, 2021
Poxel Announces its Participation at the 64th Annual Meeting of the Japan Diabetes Society May 11, 2021
